JingWatnick

[Akron Beacon Journal @beaconjournal]

Peter Mang was diagnosed with an aggressive brain tumor five years ago. With the help of a Cleveland Clinic clinic trial, his cancer is undetectable. https://t.co/Vrg8gZ6rMM

[Katie Mang @KatieMang]

Many thanks to the Akron Beacon Journal for sharing our story and shining a light on Glioblastoma and clinical trials!

We thank the @ClevelandClinic for its outstanding medical care, investment in research, and supportive staff.

[JingWatnick @JingWatnick]

Exciting day as #vigeo #nasdaq is ringing the closing bell today to raise awareness for brain cancer! It's been such a rewarding journey translating science into clinical treatments that benefit patients. So grateful for the support from our patients, oncologists and partners!

[Vigeo Therapeutics @vigeotx]

In honor of Brain Cancer Awareness month @vigeotx is proud to be included in the closing bell event at NASDAQ today

https://t.co/LMgqKKyEGe

[Vigeo Therapeutics @vigeotx]

Excellent article describing the ongoing research of @vigeotx co-founder Dr. Randy Watnick of @BostonChildrens hospital #TME #oncologyresearch #oncology https://t.co/2BdWIUjNqc

[Vigeo Therapeutics @vigeotx]

Is TSP-1 the natural enemy of Glioblastoma? Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately? #CD36 #CD47 #TSP1 #GBM #TME #immunooncology https://t.co/u10maSuft6 #mdpiijms via @IJMS_MDPI

[Vigeo Therapeutics @vigeotx]

Vigeo Therapeutics is excited to be joining the AGILE Phase 2-3 study for patients with newly diagnosed and recurrent GBM #CD36 #CD47 #oncology https://t.co/QxG7JlSlK4

[Marsha Crochiere @MarshaCrochiere]

The team at @vigeotx is growing!
https://t.co/HX4DnrPVmk

[JingWatnick @JingWatnick]

Excited to share our new clinical data at #SITC2020! #CD36 #CD47 #TME

[Vigeo Therapeutics @vigeotx]

Vigeo is in the news! #sitc2020 #CD36 #CD47 https://t.co/BAZWVQHvCF

[RSW1003 @rsw1003]

"Nationalism is an infantile sickness. It is the measles of the human race." 
[Albert Einstein, the Human Side]

[JingWatnick @JingWatnick]

#vote2020

[JingWatnick @JingWatnick]

We are hiring!

[Vigeo Therapeutics @vigeotx]

Excellent opportunity to join the Vigeo team.
https://t.co/I37CHaXVTB

[Vigeo Therapeutics @vigeotx]

Vigeo will have a poster on our Ph1/2 dose escalation and expansion study of our TSP-1 inducer, VT1021 in advanced solid tumors at #SITC2020. Data will be presented on 11/12 from 4:50 -5:20 PM ET and 11/14 from 1 -1:30 PM ET. https://t.co/N4EKwXRCgo #CD47 #CD36 #ImmunoOncology

[JingWatnick @JingWatnick]

@vigeotx @PharmaTechFocus Our deep gratitude to the team and our PIs for working diligently during COVID to actively enroll cancer patients into the study #TME #CD36 #ovariancancer #PancreaticCancer #GBM #tnbc #solidtumors #CD47 #clinicaltrials #oncology

[Vigeo Therapeutics @vigeotx]

Our CEO, Dr. Jing Watnick, weighs in on how clinical trials and patients are faring during #COVID19 in this article published in @PharmaTechFocus
#oncology
Salvaging clinical trials in the time of Covid-19 https://t.co/HXqe1ckQ9m

[Vigeo Therapeutics @vigeotx]

How do #cancer and #COVID-19 both hijack the immune system? Learn more from Vigeo CEO, Dr. Jing Watnick, in an article published in @DrugTargetRev .

[Vigeo Therapeutics @vigeotx]

Thanks to @PharmExec for publishing a thoughtful article by our President and CEO, Jing Watnick, on the struggles of maintaining cancer treatments during the COVID-19 pandemic #cancer #covid1Cancer Patients Can Not Afford To Put Their Struggle on Hold https://t.co/wLSUsgmi6c

[JingWatnick @JingWatnick]

Vigeo’s ongoing phase 2 trial is actively enrolling patients. #breastcancer #pancreaticcancer #ovarian-cancer #glioblastoma #CD36 #cancer #immunotherapy
#oncology
#cancertreatment https://t.co/HtHo9Dpa05

[Vigeo Therapeutics @vigeotx]

We are celebrating National Cancer Research Month at Vigeo. We are fortunate to be a research driven organization using our understanding of what turns the tumor microenvironment from cold to hot to bring forward new therapies for cancer patients. #NCRM20

[JingWatnick @JingWatnick]

So very proud of the Vigeo team for making this happen during the pandemic. Also truly inspired by the dedication of our investigators and the perseverance of our patients in fighting against cancer!

[Vigeo Therapeutics @vigeotx]

Vigeo is moving its clinical program forward. We have dosed our first patients in the expansion phase of our 1b/2 study investigating VT1021 in patients with CD36 expressing cancers. Read more here: https://t.co/ZrrAqtF4MO

[Vigeo Therapeutics @vigeotx]

Like many biotech companies, @Vigeotx is fortunate to be in a position to donate much needed medical supplies to local hospitals like @BIDMC. Sending gratitude and thanks on #NationalDoctorsDay to all those on the front lines of the #coronavirus crisis.